Scandion Oncology A/S receives EU-patent for SCO-101

Scandion Oncology A/S (“Scandion Oncology”) today announces that the European Patent Office (“EPO”) has granted the company’s patent application for SCO-101 when combined with chemotherapy. Patent is valid until May 2037.

The release as fetched from its publisher. scandiononcology.com ↗